Intermediate‐dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease‐free survival

Tapan K. Saikia; Suresh H. Advani; Gopal Ramakrishnan; Shanti Swaroop; Sanjay Sharma; Praful B. Desai

doi:10.1002/1097-0142(19890715)64:2<371::AID-CNCR2820640205>3.0.CO;2-1

Intermediate‐dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease‐free survival

Tapan K. Saikia, Suresh H. Advani, Gopal Ramakrishnan, Shanti Swaroop, Sanjay Sharma, Praful B. Desai

Gastroenterology and Hepatology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate‐dose methotrexate (200 mg/m² on day 1) and cisplatin (20 mg/m²/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence‐free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow‐up. Three patients are still alive and disease‐free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.

Original language	English (US)
Pages (from-to)	371-373
Number of pages	3
Journal	Cancer
Volume	64
Issue number	2
DOIs	https://doi.org/10.1002/1097-0142(19890715)64:2<371::AID-CNCR2820640205>3.0.CO;2-1
State	Published - Jul 15 1989

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19890715)64:2<371::AID-CNCR2820640205>3.0.CO;2-1

Cite this

@article{fed232027c3a4b25bc1b134228c0a48f,

title = "Intermediate‐dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease‐free survival",

abstract = "Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate‐dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence‐free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow‐up. Three patients are still alive and disease‐free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.",

author = "Saikia, {Tapan K.} and Advani, {Suresh H.} and Gopal Ramakrishnan and Shanti Swaroop and Sanjay Sharma and Desai, {Praful B.}",

year = "1989",

month = jul,

day = "15",

doi = "10.1002/1097-0142(19890715)64:2<371::AID-CNCR2820640205>3.0.CO;2-1",

language = "English (US)",

volume = "64",

pages = "371--373",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Intermediate‐dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease‐free survival

AU - Saikia, Tapan K.

AU - Advani, Suresh H.

AU - Ramakrishnan, Gopal

AU - Swaroop, Shanti

AU - Sharma, Sanjay

AU - Desai, Praful B.

PY - 1989/7/15

Y1 - 1989/7/15

N2 - Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate‐dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence‐free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow‐up. Three patients are still alive and disease‐free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.

AB - Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate‐dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence‐free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow‐up. Three patients are still alive and disease‐free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0024364627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024364627&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19890715)64:2<371::AID-CNCR2820640205>3.0.CO;2-1

DO - 10.1002/1097-0142(19890715)64:2<371::AID-CNCR2820640205>3.0.CO;2-1

M3 - Article

C2 - 2736483

AN - SCOPUS:0024364627

SN - 0008-543X

VL - 64

SP - 371

EP - 373

JO - Cancer

JF - Cancer

IS - 2

ER -

Intermediate‐dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease‐free survival

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this